Affordable Access

deepdyve-link
Publisher Website

Omics Derived Biomarkers and Novel Drug Targets for Improved Intervention in Advanced Prostate Cancer.

Authors
  • Frantzi, Maria1
  • Hupe, Marie C2
  • Merseburger, Axel S2
  • Schanstra, Joost P3, 4
  • Mischak, Harald1, 5
  • Latosinska, Agnieszka1
  • 1 Mosaiques Diagnostics GmbH, 30659 Hannover, Germany. , (Germany)
  • 2 Department of Urology, University Hospital Schleswig-Holstein, Campus Lübeck, 23538 Lübeck, Germany. , (Germany)
  • 3 Institut National de la Santé et de la Recherche Médicale (INSERM) U1048, Institute of Cardiovascular and Metabolic Diseases, 31432 Toulouse, France. , (France)
  • 4 Université Toulouse III Paul-Sabatier, 31400 Toulouse, France. , (France)
  • 5 Institute of Cardiovascular and Medical Sciences, University of Glasgow, G12 8TA Glasgow, UK.
Type
Published Article
Journal
Diagnostics (Basel, Switzerland)
Publication Date
Aug 31, 2020
Volume
10
Issue
9
Identifiers
DOI: 10.3390/diagnostics10090658
PMID: 32878288
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Prostate cancer (PCa) is one of the most frequently diagnosed malignancies, and the fifth leading cause of cancer related mortality in men. For advanced PCa, radical prostatectomy, radiotherapy, and/or long-term androgen deprivation therapy are the recommended treatment options. However, subsequent progression to metastatic disease after initial therapy results in low 5-year survival rates (29%). Omics technologies enable the acquisition of high-resolution large datasets that can provide insights into molecular mechanisms underlying PCa pathology. For the purpose of this article, a systematic literature search was conducted through the Web of Science Database to critically evaluate recent omics-driven studies that were performed towards: (a) Biomarker development and (b) characterization of novel molecular-based therapeutic targets. The results indicate that multiple omics-based biomarkers with prognostic and predictive value have been validated in the context of PCa, with several of those being also available for commercial use. At the same time, omics-driven potential drug targets have been investigated in pre-clinical settings and even in clinical trials, holding the promise for improved clinical management of advanced PCa, as part of personalized medicine pipelines.

Report this publication

Statistics

Seen <100 times